ProCE Banner Activity

GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian Cancer

Slideset Download
Conference Coverage
Prior bevacizumab did not adversely affect efficacy or safety of subsequent bevacizumab retreatment in recurrent platinum-sensitive ovarian cancer.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals